HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target on the stock.
December 04, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Cocrystal Pharma with a maintained price target of $12.
The reiteration of a Buy rating and the maintenance of a $12 price target by a reputable analyst could instill confidence in investors and positively influence Cocrystal Pharma's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100